GLPwatch
Papers (9189)
Page 93 of 154, ranked by citation count.
- Add-on value of tirzepatide versus semaglutide.
- GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials.
- Pancreatic safety of newer incretin-based therapies: are the "-tides" finally turning?
- GLP-1 agonist associated acute kidney injury: A case report and review.
- Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.
- Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model.
- Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
- Glucagon-like peptide-1 analog, liraglutide, regulates Sertoli cell energy metabolism.
- Semaglutide once-weekly: improved efficacy with a new safety warning.
- Pyoderma gangrenosum associated with dulaglutide therapy.
- Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?
- Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis.
- Comparison of nephron-protective effects of enalapril and GLP analogues (exenatide) in diabetic nephropathy.
- Cost-Effectiveness of Semaglutide in Patients With Obesity and Cardiovascular Disease.
- Tirzepatide for Weight Loss: Can Medical Therapy "Outweigh" Bariatric Surgery?
- Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.
- The Antidiabetic Drug Liraglutide Minimizes the Non-Cholinergic Neurotoxicity of the Pesticide Mipafox in SH-SY5Y Cells.
- Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
- L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
- GLP-1R knockdown abrogates the protective effects of liraglutide on ischaemic stroke via inhibition of M2 polarisation and activation of NLRP3 inflammasome by reducing Nrf2 activation.
- Albiglutide for the management of type 2 diabetes.
- Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.
- Current perspectives in obesity management: unraveling the impact of different therapy approach in real life obesity care.
- Analysis of the effect of liraglutide on glycemic variability in patients with type 2 diabetes.
- Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control.
- Biological activity of EXf, a peptide analogue of exendin-4.
- Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality.
- Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.
- New hope for devastating neurodegenerative disease.
- Exendin-4 improves ER stress-induced lipid accumulation and regulates lipin-1 signaling in HepG2 cells.
- Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.
- Targeting obesity for therapeutic intervention in heart failure patients.
- Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
- Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
- Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins.
- The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
- hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.
- The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
- Comparative efficacy and safety of semaglutide 2.4 mg and tirzepatide 5-15 mg in obesity with or without type 2 diabetes: A systematic review of Phase 3 clinical trials.
- Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
- A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.
- Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study.
- Pseudo-Wang Handle for the Preparation of Fully Protected Peptides. Synthesis of Liraglutide by Fragment Condensation.
- Safety of Once-weekly Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3.
- GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner.
- The GLP-1 analog exendin-4 modulates HSP72 expression and ERK1/2 activity in BTC6 mouse pancreatic cells.
- Mono-PEGylates of exenatide in branched and dimeric structures can improve in vivo stability and hypoglycemic bioactivity.
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.
- The effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients.
- On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide.
- Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
- Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
- Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison.
- Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation.
- A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.
- Exploring Hypoglycemic Ketoacidosis in Nondiabetic Patients on Tirzepatide: Is Starvation the Culprit?
- Novel Trajectories Towards Possible Effects of Semaglutide for Amelioration of Reserpine-induced Fibromyalgia in Rats: Contribution of cAMP/PKA/p-CREB and M1/M2 Microglia Polarization.
- Glucagon-like peptide-1 receptor differentially controls mossy cell activity across the dentate gyrus longitudinal axis.
- Titration and discontinuation of semaglutide for weight management in commercially insured US adults.